Form 4: CytoDyn Director Granted Annual Stock Options

CytoDyn Inc. Director Lishomwa C Ndhlovu received an annual grant of 574,385 non-qualified stock options with an exercise price of $0.28, vesting monthly over one year.

Summary

• Lishomwa C Ndhlovu, a Director of CytoDyn Inc. (CYDY), was granted 574,385 non-qualified stock options.
• The options have an exercise price of $0.28 per share.
• The grant was approved by the Company's Compensation Committee on March 20, 2026.
• This grant represents the annual award for fiscal year 2026, consistent with past practice.
• The options were issued under the Issuer's 2012 Equity Incentive Plan, as amended.
• The stock options will vest in 12 approximately equal monthly installments, beginning April 2026 through March 2027.
• The expiration date for these options is March 20, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine event. While not a major catalyst, it reflects standard corporate governance and aligns director incentives with shareholder value, which is generally favorable.

Positives

• The grant aligns the director's interests with those of shareholders through equity ownership.
• It represents a routine annual compensation practice, indicating stable corporate governance regarding executive and director incentives.

Future Outlook

The vesting schedule indicates a commitment for the director's continuous service through March 2027 to fully realize the equity grant. The long expiration date provides flexibility for future exercise.

Management Comments

• This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice across industries. It serves to align the interests of the board members with those of the shareholders, incentivizing long-term performance and value creation. This type of compensation is a standard component of director remuneration packages, particularly in growth-oriented sectors like biotechnology.

Comparison to Industry Standards

• Equity compensation for directors, such as stock options, is a widely adopted practice, comparable to companies like Amgen Inc. (AMGN) or Gilead Sciences, Inc. (GILD) which also utilize equity plans to incentivize their leadership.
• The vesting schedule over 12 months is a typical structure designed to encourage continued service and commitment, similar to many peer companies in the pharmaceutical and biotech sectors.
• The exercise price being set at the market price on the grant date (implied by a $0 price of derivative security and a specific exercise price) is standard for non-qualified stock options.

Corporate Governance

Related Party Transactions

• The grant of stock options to Lishomwa C Ndhlovu, a Director, constitutes a related party transaction. However, it is a standard form of director compensation approved by the Compensation Committee and consistent with the company's established equity incentive plan.

Stakeholder Impact

• Shareholders: The grant aims to align the director's long-term interests with shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: No direct impact on general employees is noted in this filing, but the use of the 2012 Equity Incentive Plan suggests a broader framework for equity compensation.

Next Steps

• The stock options will vest in 12 approximately equal installments on the same day of each month of Continuous Service beginning April 2026 through March 2027.

Key Dates

Recommendation

This Form 4 reports a routine annual equity grant to a director, consistent with past practices. It does not introduce new material information that would significantly alter the company's financial outlook or operational performance. Therefore, it does not warrant a change in investment recommendation, and a 'hold' stance is appropriate for existing investors.

Keywords

CytoDyn, CYDY, stock options, director compensation, insider transaction, equity incentive plan, Form 4